Seres Therapeutics Corporate Overview Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including, but not limited to the potential approval and launch of SER-109; the anticipated indication for SER-109; the anticipated supply of SER-109; the potential for microbiome therapeutics to protect against infection; the timing of clinical development; our development opportunities and plans; the ultimate safety and effica ...

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Carlo Tanzi - IR Officer Eric Shaff - President, CEO & Director Teresa Young - EVP and Chief Commercial & Strategy Officer Lisa von Moltke - EVP & Chief Medical Officer David Arkowitz - EVP, CFO & Head, Business Development David Ege - EVP & CTO Matthew Henn - EVP & Chief Scientific Officer Conference Call Participants Mark Breidenbach - Oppenheimer John Newman - Canaccord Genuity Edward Ten ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37465 le Seres Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 27-4326290 (State or Other Jurisdict ...

Corporate Overview November 2022 2 Forward Looking Statements Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including, but not limited to the potential approval and launch of SER-109; the anticipated indication for SER-109; the anticipated supply of SER-109; the potential for microbiome therapeutics to protect against infection; the timing of clinical results; our development opportunities and plans; the ultima ...

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2022 Earnings Conference Call November 2, 2022 8:30 AM ET Company Participants Carlo Tanzi - Head of Investor Relations Eric Shaff - President & Chief Executive Officer Lisa von Moltke - Chief Medical Officer Matthew Henn - Chief Scientific Officer David Arkowitz - Chief Financial Officer Teresa Young - Chief Commercial & Strategy Officer Conference Call Participants Peyton Bohnsack - Cowen Ted Tenthoff - Piper Sandler Mark Breidenbach - Oppenheimer John Newman - Ca ...

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants Carlo Tanzi - Head of IR Eric Shaff - President & CEO Lisa von Moltke - Chief Medical Officer Matthew Henn - Chief Scientific Officer David Arkowitz - CFO Terri Young - Chief Commercial and Strategy Officer David Ege - Chief Technology Officer Conference Call Participants Mark Breidenbach - Oppenheimer Peyton Bohnsack - Cowen John Newman - Canaccord Ted Tenthoff - Piper Sandler Chris Howert ...

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Carlo Tanzi - Head of Investor Relations Eric Shaff - President and Chief Executive Officer Lisa von Moltke - Chief Medical Officer Matthew Henn - Chief Scientific Officer David Arkowitz - Chief Financial Officer Terri Young - Chief Commercial and Strategy Officer David Ege - Chief Technology Officer Conference Call Participants Mark Breidenbach - Oppenheimer Peyton Bohnsack - Cowen John Newma ...

Corporate Overview March 2022 2 Forward Looking Statements Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including, but not limited to, the potential approval of SER-109 and its status as a first-in-class therapeutic, the timing of a BLA filing, the market for SER-109, and our capacity for commercial supply of SER-109; the anticipated indication and potential impact of infection protection microbiome therapeuti ...

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2021 Earnings Conference Call March 1, 2022 8:30 AM ET Company Participants Carlo Tanzi - Investor Relations Eric Shaff - President and Chief Executive Officer Lisa von Moltke - Chief Medical Officer Matthew Henn - Chief Scientific Officer David Arkowitz - Chief Financial Officer Terri Young - Chief Commercial and Strategy Officer Conference Call Participants Edward Tenthoff - Piper Sandler Peyton Bohnsack - Cowen Inc. John Newman - Canaccord Genuity Group Inc. Gobi ...

Call Start: 8:30 January 1, 0000 9:13 AM ET Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2021 Earnings Conference Call November 10, 2021, 8:30 AM ET Company Participants Carlo Tanzi ??? Investor Relations Eric Shaff ??? President and Chief Executive Officer Lisa von Moltke ??? Chief Medical Officer David Arkowitz ??? Chief Financial Officer Matthew Henn ??? Chief Scientific Officer Terri Young ??? Chief Commercial and Strategy Officer David Arkowitz ??? Chief Technology Officer Conference Call Participants Jo ...